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Abstract
The age of liver donors has been increasing in the 
past several years because of a donor shortage. In the 
United States, 33% of donors are age 50 years or older, 
as are more than 50% in some European countries. 
The impact of donor age on liver transplantation (LT) 
has been analyzed in several studies with contradictory 
conclusions. Nevertheless, recent analyses of the 
largest databases demonstrate that having an older 
donor is a risk factor for graft failure. Donor age is 
included as a risk factor in the more relevant graft 
survival scores, such as the Donor Risk Index, donor 
age and Model for End-stage Liver Disease, Survival 
Outcomes Following Liver Transplantation, and the 
Balance of Risk. The use of old donors is related to an 
increased rate of biliary complications and hepatitis 
C virus-related graft failure. Although liver function 
does not seem to be significantly affected by age, the 
incidence of several liver diseases increases with age, 
and the capacity of the liver to manage or overcome 
liver diseases or external injuries decreases. In this 
paper, the importance of age in LT outcomes, the role 
of donor age as a risk factor, and the influence of aging 
on liver regeneration are reviewed.
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Core tip: Because of a donor shortage, the use of grafts 
from old donors has become widespread. Donor age is 
from donors younger than 55 years vs donors older 
than 65 years (65% vs 57%, P < 0.0001)[1]. An 
analysis of the data collected by the Spanish Registry 
for Liver Transplantation between 1991 and 2013 
shows that donor age influences LT outcome (Figure 
3). LT performed with deceased donors over age 55 
years had a slight but significant worsening in actuarial 
graft survival one year after LT compared with those 
realized with graft from donors younger than 55 years. 
The difference in graft survival between the two groups 
was more evident at 5 years after LT[3]. Feng et al[10] 
recently analyzed donor risk factors in LTs  finding  that 
donor age over 60 years was the strongest risk factor 
for graft failure. In this analysis of the data collected 
from the Scientific Registry of Transplant Recipients, 
donor age over 40 years and especially over 60 
years, donation after cardiac death, and split/partial 
grafts were strongly associated with graft failure. In a 
retrospective analysis performed using data obtained 
from the UNOS, Reese et al[11] found that performing 
LTs with donors who were ≥ 45 years old increased 
the risk of graft failure at 90 d after transplantation. 
Moreover, these authors found that a combination of 
prolonged cold ischemia time and older donor age 
were associated with a decrease in graft survival after 
LT.  We performed a prospective analysis to establish 
if donor age over 60 years could be a risk factor for 
higher incidence of complications or graft failure[12]. We 
did not observe differences in the initial graft function 
between groups. Moreover in the older donor group 
we did not observe any case of primary non-function 
and patient survival was not affected. Nevertheless, 
graft survival at 12 mo was decreased by about 15% 
in the older donor group, although patient survival was 
not affected. 
Other studies show different results. Anderson et 
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Figure 1  Change in distribution of donor age in recent years. Source: 
Spanish Liver Transplant Registry.
related to worse outcomes after liver transplantation, 
higher rates of graft failure, biliary complications and 
a worse graft survival. In recipients with hepatitis 
C, the impact of donor age is even more evident. 
Aging-related changes at the hepatocellular level 
may contribute to a decreased capacity of the liver to 
manage or overcome liver diseases and injuries. This 
review summarizes the evidence regarding the impact 
of donor age on liver transplantation outcomes. 
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INTRODUCTION
In the recent years a considerable change in donor 
age distribution of liver transplantation (LT) has been 
observed, as shown in the figures from the European 
Liver Transplant Registry (ELTR), with a rising 
percentage of livers proceeding from donors older than 
60 years. In 1989, only 1% of livers proceeded from 
donors over 60 years of age. This rate escalates to 
15% in 1999, 20% in 2001, and 29% in 2009[1,2]. In 
Spain, between 1984 and 1995, only 11.5% of donors 
were age 55 years or older, while between 2011 and 
2012, 61.8% of donors were 55 years or older (Figure 
1)[3]. The United Network for Organ Sharing (UNOS), 
in the United States, reports that in 1989, 2.4% 
of donors were age 50 years or older, but this rate 
increased to 29% in 1999 and to 33% in 2013 (Figure 
2).
The impact of donor age on LT has been evaluated 
in different studies with contradictory results. Many 
studies did not observe differences in graft survival 
according to donor age[4,5], on the contrary others 
report an increases of complication rates and poorer 
survival following transplantation from older donors[6,7]. 
Furthermore, a relationship has been described 
between allografts obtained from older donors and 
a faster progression of fibrosis after LT in recipients 
infected with hepatitis C virus (HCV)[8,9].
IMPACT OF DONOR AGE ON LIVER 
TRANSPLANT OUTCOMES
Deceased donor liver transplant
Studies based on institutional registries have evaluated 
the effects of donor age on patient and graft survival in 
the largest patient series[1-3,6,7]. In the ELTR, the 1-year 
survival of patients who received transplants between 
1998 and 2001 was similar for all donor age groups[2]. 
In a recent analysis of the same ELTR database, graft 
survival was significantly higher if the organs proceed 
al[13] analyzed 741 LTs performed between 1990 and 
2007 and did not found significant difference in overall 
graft and patient survival with donors younger than 60 
years compared to those aged 60 or older. However, 
when cases with donors ≥ 60 years were compared 
with each other from different time period, the authors 
observed that the LT performed after 2001 had a 
better patient and graft survival. LT performed before 
2001 had significantly longer cold ischemic times 
compared with those performed after 2001. From this 
study, these authors concluded that donor age per se 
is not a disadvantage for graft or patient survival, but 
that there was a possible interaction between donor 
age and other factors such as ischemia time. 
Alamo et al[14] conducted a case-control single-
center study and examined the outcomes of 129 livers 
transplanted from donors older than age 70 years. 
The authors observed no differences in survival but 
did identify a greater incidence of ascites and primary 
dysfunction, probably secondary to a delayed start in 
graft function. They recognized that recipient Model 
for End-Stage Liver Disease (MELD) score and cold 
ischemia time were parameters associated with a poor 
prognosis. In addition the authors found that some 
donor factors were associated with a poor prognosis: 
diabetes, hypertension, and weight greater than 90 
kg. With these results, this group concluded that LT 
with liver grafts from elderly donors is safe but that the 
selection of donors and recipients must be done with 
care. Kim et al[15] retrospectively analyzed outcomes 
of LT using livers from donors age 65 years and older 
and tried to identify those factors that affected graft 
survival. The results indicated that these factors were 
hepatitis C as the etiology of liver disease, MELD score 
higher than 20, donor serum glucose level higher 
than 200 mg/dL at the time of liver recovery, and 
skin incision to aortic cross-clamp time longer than 40 
min in the donor surgery. In the analysis, the authors 
observed that the 5-year cumulative graft survival 
rate of none, one, two, three, and four unfavorable 
characteristics was 100%, 82%, 81.7%, 39.3%, and 
25%, respectively (P < 0.05). The authors suggested 
that the grafts from older donors should not be 
considerate useless based only on age and that in 
selected cases, they can result in good graft survival. 
All these studies are summarized in the Table 1.
Living donor liver transplant
Han et al[16] recently demonstrated that living donor 
LT (LDLT) using elderly donors, defined as those ≥ 
55 years of age, could be related with more serious 
complications and higher mortality rates. In that 
retrospective analysis including 604 LDLTs, the 
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Figure 2  Change in distribution of donor age in recent years. Source: United Network for Organ Sharing reports.
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Figure 3  Graft survival depending on donor age. Source: Spanish Liver 
Transplant Registry.
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from donors ≤ 50 years old. In addition, Iwamoto et 
al[20] reported significantly higher bilirubin levels and 
worse survival following transplantations using donors 
age 50 years or older. Recently, Ono et al[21] analyzed 
hepatic regeneration in living donors and observed that 
the regeneration rate a week after hepatectomy was 
significantly higher in donors who were ≤ 30 years old 
than in those ≥ 50 years old; however, the differences 
disappeared within a month after LT.
These results are consistent with the more recent 
work of Uchiyama et al[22], who retrospectively analy-
zed 321 consecutive LDLTs performed between 2004 
and 2014 and found that donor age was a significant 
risk factor for small-for-size graft syndrome. In the 
conclusions, the authors suggest that the use of 
hepatic grafts from older donors should be avoided if 
possible to minimize post-transplant complications[22].
On the contrary Li et al[23], in a retrospective analysis, 
found no differences in complication rates and recipient 
survival at 1, 3, and 5 years. These data suggest that 
LDLT using older donors had no negative influence on 
the outcomes of both donors and recipients.
These results are consistent with other recent 
studies. Wang et al[24] analyzed the outcome of 159 
LDLTs divided by donor age into older or younger than 
50 years and found no significant difference in graft or 
recipient survival at 1, 3, and 5 years. However, the 
volume of red blood cells transfused during the surgical 
procedure was greater in the older donor group (1.900 
mL vs 1.200 mL, P = 0.023). From these results, the 
authors suggested that LDLT with donors older than 
50 years old is safe and that there are not significant 
adverse effects in terms of graft function and long-
term donor and patient survival. All these studies are 
mortality rate was significantly higher in the elderly vs 
the younger donor group. The 5-year survival rate was 
44.6% in the elderly group and 80.7% in the younger 
group, and the median overall survival was significantly 
shorter in the elderly group (31.2 ± 31.3 mo vs 51.4 
± 40.8 mo, P = 0.014). Biliary (41.7%) and arterial 
complications (16.7%) were the more frequent 
causes of death in the elderly group, which were both 
significantly higher than in the younger group. This 
study was limited because of its retrospective analysis 
that included a small number of patients in the elderly 
group; nevertheless, the results suggest that donor 
age directly affects overall survival and complication 
rate in LDLT. 
Another recent study[17] demonstrated a significant 
association between surgical technique aspects 
and the rate of major complications when grafts 
from donors aged ≥ 50 years are used. In LDLT, 
enlarging the limits of surgery is associated with more 
complications in elderly donors. With donors who are 
≥ 50 years old, these authors recommend avoiding 
right hepatectomy with middle hepatic vein harvesting 
or resulting in an estimated remnant liver volume less 
than 35%. Other reports suggest that donor age might 
have a major effect on recipient outcome in adult 
LDLT. Ikegami et al[18] demonstrated that LT performed 
with living donors ≤ 30 years old resulted in better 
function and regeneration rates within the first month 
than those performed with donors > 50 years of age. 
However, the outcome was not affected by the age of 
the liver graft. In a further study[19], the same authors 
demonstrated a greater incidence of small-for-size 
syndrome in recipients from living donors older than 
50 years compared to those transplanted with livers 
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Table 1  Studies that analyze impact of donor age on liver transplant outcomes
Ref. Type of donor Cut-off age No. of patients Outcomes
Adam et al[1] Deceased donor < 55 yr vs > 65 yr 80347 Higher graft survival with donors younger than 55 yr
Adam et al[2] Deceased donor Multiple age groups 41522 No differences in one-year survival
Cuervas-Mons et al[3] Deceased donor 55 yr 18568 Lower graft 5-yr survival rate with older donors
Feng et al[10] Deceased donor 60 yr 20023 Higher rate of graft failure with older donors
Reese et al[11] Deceased donor 45 yr 14756 Higher rate of graft failure at 90 d after LT with older donors
Serrano et al[12] Deceased donor 60 yr     149 Lower graft survival rate with older donors
Anderson et al[13] Deceased donor 60 yr     741 No differences were observed
Alamo et al[14] Deceased donor 70 yr     129 No differences were observed in selected recipients 
(non HCV, low MELD, younger than 60 yr)
Kim et al[15] Deceased donor 65 yr     100 Donor age should not be an absolute contraindication
Han et al[16] Living donor 55 yr     604 Higher mortality rate with older donors
Dayangac et al[17] Living donor 50 yr     150 Higher rate of major complication with older donors
Ikegami et al[18] Living donor < 30 yr vs > 50 yr       34 Better graft function and regeneration rates with donors < 30 yr
Ikegami et al[19] Living donor 50 yr     232 Higher rate of small for size syndrome with older donors
Iwamoto et al[20] Living donor 50 yr     232 Worse survival and high bilirubin levels with older donors
Ono et al[21] Living donor < 30 yr vs > 50 yr       15 Lower regeneration rate a week after LT with older donors
Uchiyama et al[22] Living donor 48 yr     321 Higher rate of small for size syndrome with older donors
Li et al[23] Living donor 70 yr     129 No differences in recipient survival rate at 1, 3 and 5 yr
Wang et al[24] Living donor 50 yr     159 No differences in recipient survival rate at 1, 3 and 5 yr
LT: Liver transplantations; HCV: Hepatitis C virus; MELD: Model for End-stage Liver Disease.
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summarized in the Table 1.
DONOR AGE AS RISK FACTOR IN 
PROGNOSTIC SCORES
In the past several years, donor quality has been 
decreasing. Some studies have tried to detect the most 
important risk factors and to develop several mathe-
matical formulas designed to predict graft outcome. 
All of them include donor age as a risk factor (Table 
2). Feng et al[10] performed one of the most relevant 
studies; this group used the UNOS database  to 
identify eight donor factors predicting graft failure after 
transplantation (donor age, donor height, donation 
after cardiac death, split liver donor, black race, 
vascular accident as cause of death, regional sharing, 
and cold ischemia time). A donor risk index (DRI) 
was developed, using these risk factors, to predict 
the isolated and cumulative effects of these variables 
on graft survival. Recipients of grafts with a DRI < 
1.2 had a graft survival higher than 80% per year vs 
71.4% in those transplanted with organs with a DRI 
> 2. In that study, donor age over 60 years was the 
strongest risk factor for graft failure (relative risk = 1.53 
with a donor > 60; 1.65 if > 70). However, this index 
is not easily applicable in every country. In Europe, 
Eurotrasplant region database analysis showed that 
donor age (P < 0.0001), donation after cardiac death (P 
= 0.001), split/partial liver (P < 0.0001), latest serum 
GGT gamma-glutamyl transpeptidase (P = 0.006), 
allocation (P < 0.0001), and rescue allocation (P = 
0.005) were significantly associated with an increased 
risk of graft failure. These six factors were used to 
construct a “new theoretical Eurotransplant risk index”[25].
Because post-transplantation patient survival 
depends on both the preoperative medical condition 
and donor quality, physicians often face the difficult 
decision of whether to accept high-risk donor liver 
offers for high-risk patients. Thus, in contrast with DRI, 
the Survival Outcomes Following Liver Transplantation 
(SOFT) score includes donor and recipient factors 
and also ischemia times[26]. The overall result of the 
score could guide the clinician to either accept or 
reject the offered allograft, based on the projected 
risk calculation. Authors proposed that cold ischemia 
time might be estimated when the offer is performed. 
Donor age > 70 is the donor variable that has a 
greater weight in the SOFT score[26]. Halldorson et al[27] 
tried to identify poor donor/recipient matches that 
could help to direct allocation of organs to recipients 
in which the survival is greatest, maximizing the 
benefit of donor livers. They created the D-MELD 
score, which was calculated as the product of the 
MELD score and donor age and was demonstrated 
to be highly predictive of post-LT survival. A D-MELD 
cut-off of 1600 identified donor/recipient combinations 
with significantly poorer survival. This score could 
predict excessive donor/recipient match risk and 
improve resource use. Another risk score described 
by Dutkowski et al[28] is the balance of risk system, 
which detects unfavorable combinations of donor and 
recipient factors. It analyzes six factors including donor 
age. In summary, donor age is a variable included in 
all main scores that analyze the risk of death and graft 
loss after LT and is one of the factors that weighs the 
most in these models.
LIVER AGE AS RISK FACTOR IN LIVER 
TRANSPLANT COMPLICATIONS
Donor age also has been described as a risk factor 
in development of some specific complications such 
as biliary and aggressive recurrence of HCV. Here we 
describe the studies that support these data.
Biliary complications
In recent years, numerous studies have shown that 
donor age may be related to a higher prevalence 
of biliary strictures. Thorsen et al[29] found that LTs 
performed with donors older than 75 years presented 
more biliary complications when compared with those 
patients who received a graft from donors aged 20 
to 49 years (29.6% vs 13%). However, survival did 
not differ between groups. Verdonk et al[30] found 
that the incidence of anastomotic strictures (AS) 
increased from 5.3% before 1995 to 16.7% after 
1995, possibly related to an increase in the use of 
grafts from donors with extended criteria. Similarly, 
Sundaram et al[31] found that biliary AS rate increases 
after the introduction of MELD for graft allocation 
(6.4% in the pre-MELD era vs 15.4% in the post-
MELD era). Transplantation in the post-MELD era was 
an independent risk factor for biliary AS (OR = 2.30; 
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Table 2  Variables included in the most relevant survival scores
Model Variables included Ref.
DRI D-age, donor height, DCD, split, race, 
COD, allocation, CIT
Feng et al[10]
ET-DRI D-age, DCD, Partial/Split, GGT, 
allocation, rescue allocation
Braat et al[25]
SOFT D-age, COD, donor creatinine, R-age, 
R-BMI, previous OLT, previous 
abdominal surgery, R-albumin, 
dialysis, UNOS status, MELD score, 
encephalopathy, PVT, ascites, portal 
bleed, life support, allocation, CIT
Rana et al[26]
D-MELD D-age, MELD score Halldorson et al[27]
BAR MELD score, CIT, R-age, D-age, 
previous OLT, life support
Dutkowski et al[28]
COD: Cause of death; CIT: Cold ischemia time; DCD: Donation after 
cardiac death; DRI: Donor risk index; D-age: Donor age; ET-DRI: 
Eurotrasplant donor risk index; SOFT: Survival outcomes following liver 
transplantation; R-age: Recipient age; OLT: Orthotopic liver transplant; 
PVT: Portal vein thrombosis; D-MELD: Donor age Model for End-stage 
Liver Disease; BAR: Balance of risk.
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95%CI: 1.60-3.32, P = 0.001). Other risk factors were 
donor age (OR = 1.01; 95%CI: 1.00-1.02, P = 0.015), 
a prior bile leak (OR = 2.24; 95%CI: 1.32-3.76, P = 
0.003), and a choledochocholedochostomy (OR = 2.22; 
95%CI: 1.23-4.06, P = 0.008). Nevertheless, in most 
studies, age was not a risk factor for AS, but it is in 
non-AS. Lüthold et al[32] in a recent study in a pediatric 
population showed that risk factors for intrahepatic 
biliary strictures were donor age over 48 years 
(increase 1.09 fold) and MELD score higher than 30 
(increase 1.2 fold). Heidenhain et al[33] analyzed nearly 
2000 patients retrospectively and found that donor 
age (P = 0.028) and cold ischemia time (P = 0.002) 
were significant risk factors for the development of 
ischemic-type biliary lesions after liver transplant. 
In the study performed by our group and 
mentioned above, we detected that non-anastomotic 
biliary strictures (NAS) were four times more frequent 
in the older donor group. In multivariate analysis 
(stepwise multiple logistic regression was performed) 
receiving a graft from a donor 60 years or older (OR 
= 4.2; 95%CI: 1.24-13.35, P < 0.01) and arterial 
complications (AC) (OR = 67; 95%CI: 11.39-394, P < 
0.0001) were both independent risk factors associated 
with NAS. Almost one half of the LT patients with 
NAS did not have arterial thrombosis. In the logistic 
regression analysis donor age ≥ 60 years, emerge 
as an independent risk factor for intrahepatic non-
ischemic strictures (OR = 15.4; 95%CI: 1.42-168.1, P 
= 0.024)[12]. NAS development in these cases could be 
related to ischemia-reperfusion injury.  Despite there 
were no differences in ischemia time between the two 
groups it is possible that grafts from older donors were 
less tolerant to ischemic reperfusion injury. Similar 
complications have been described with non-beating-
heart liver donors; the incidences of both NAS and 
ischemia-reperfusion injury is higher than with beating-
heart donors[34]. Experimental data demonstrated 
that ischemia-reperfusion injury significantly affects 
the biliary tree. In vitro studies performed on human 
samples have demonstrated histological and molecular 
changes in the bile duct that are related to ischemic 
injury and indicate that biliary tract is the most 
sensitive structure to this type of injury[35]. Cells from 
bile duct are more exposed to re-oxygenation damage 
because they express lower levels of glutathione than 
hepatocytes[36].
In a recent work, Ghinolfi et al[37] demonstrated 
than LT with liver of donors older than 80 years of age 
is associated with a higher rate of NAS. Nevertheless 
the authors suggest that, with appropriate donor/
recipient selection, suitable outcomes can be achieved. 
A higher MELD recipient and donor hemodynamic 
instability were associated with NAS and poorer graft 
survival[37].
HCV reinfection
The deleterious effect of donor age on the recurrence 
of HCV infection has been fully demonstrated. 
Berenguer et al[8] reported that the survival of tran-
splant patients with HCV infection is decreasing, and 
aging donors is one of the main factors. Donor age 
is an independent factor associated with the risk of 
developing cirrhosis and decreased survival. Lake et 
al[38], using data from the American Scientific Registry 
of Transplant Recipients, analyzed the impact of 
donor age on the survival of 778 hepatitis B, 3463 
hepatitis C, and 7429 non-viral recipients. In HCV-
infected recipients, the strongest predictor of graft 
loss was donor age. Transplantation with organs from 
donors between ages 41 and 50, 51 and 60, and > 
60 years old was associated with a linear increase in 
the risk of graft loss. Subsequent single or multicenter 
studies confirmed these findings[39-43]. Analysis of the 
Spanish Registry for Liver Transplantation presented 
a lower graft survival in HCV-infected patients when 
organs were procured from donors older than 50 
years[43] (Figure 4). Ghinolfi et al[39] analyzed the use 
of octogenarian donors for LT. In those ≥ 80 years old, 
the 5-year graft survival was lower for HCV-positive vs 
HCV-negative recipients (62.4% vs 85.6%, P = 0.034).
A correlation between accelerated fibrosis and 
worse outcome in grafts from older donors has been 
demonstrated[9,44]. Machicao et al[9] and Wali et al[44] 
reported that donors age 50 years or more had a 
median fibrosis progression rate of 2.7 units/year 
and time to cirrhosis of 2.2 years post-transplant. 
Donor age was also a strong factor in determining the 
likelihood of antiviral treatment success[45,46].
The impact on the LT outcomes of new direct-
acting antiviral agents (DAA) against HCV has not 
been well established. These new drugs allow more 
simple treatment regimens and minimal toxicity, and 
when used in combination, achieve viral eradication 
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Figure 4  Graft survival in hepatitis C virus-infected patients depending on 
donor age. Source: Spanish Liver Transplant Registry. 
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in most HCV patients who undergo treatment[47,48]. 
The high cost of DAA still limits treatment on a large 
scale in most countries. In the next decades, DAA 
may lead to a significant reduction in patients needing 
a liver transplant for HCV and improve graft survival 
rate by decreasing the reinfection rate after LT[49]. In 
HCV-positive recipients, the impact of donor age on LT 
outcomes may someday be the same as that if HCV-
negative recipients.
LIVER REGENERATION AND AGING
Morphological and structural changes occur in the liver 
with aging. At the macroscopic level, the liver suffers 
a reduction in size and a decline in blood flow[50,51]. At 
the hepatocellular level, changes include a loss of the 
smooth endoplasmic reticulum, a loss in the number 
of mitochondria accompanied by an increase in their 
volume, an increase in the volume of the dense body 
compartment (secondary lysosomes, residual bodies, 
lipofuscin), and an increase in hepatocyte polyploidy[52]. 
Despite morphological changes, the performed clinical 
studies do not allow for the identification of important 
age-associated deficits in liver function, and it is 
generally assumed that the majority of liver functions 
are relatively well maintained with age[53]. 
Although age does not seem to significantly affect 
liver function, the incidence of several liver diseases 
increases with age whereas the capacity of the liver 
to manage or overcome liver diseases or external 
injuries decreases. In fact, the most dramatic and 
well-documented effect of aging in the liver is the 
impairment of liver regeneration. Hepatocytes are 
normally quiescent cells, but in response to liver injury, 
they can undergo extensive replication to restore 
the liver. This cellular transition from quiescence to 
proliferation requires activation of S-phase and mitotic-
specific genes. However, fewer hepatocytes in elderly 
humans enter S-phase in comparison to younger 
people, and those that do are slower in doing so, 
compromising the rate of liver regeneration[53]. 
The loss of liver regenerative capacity is expressed 
by the decrease in cell cycle and the increase in 
autophagy and apoptosis[54]. However, despite these 
phenomena, reported over 50 years ago, the cellular 
and molecular basis for the loss of an aged liver’s 
regenerative capacity has not been fully elucidated.
Different mechanisms have been suggested as 
implicated in the loss of this capacity with aging. 
Reduction in hepatocyte telomere length is one of 
these suggested mechanisms because it diminishes 
cell mitosis and apoptosis and thus produces a decline 
in cell proliferation. Takubo et al[55], after studying 
liver specimens from 94 individuals aged 0-101 
years, found significant telomere shortening with 
age. Similar results were also observed in studies by 
Aikata et al[56] and Aini et al[57]. Hepatocytes presenting 
telomere shortening and karyotypic alterations were 
found in long-term transplanted human allografts. It 
appears that telomere shortening in liver cells is more 
significant in the early years, before the age of 40, 
when tissue turnover and growth are elevated[55,58]. 
This timing should be taken into consideration when 
comparing studies with controversial results because 
different donor age ranges were used.
Despite the clear connection between telomere 
shortening and reduction in cell proliferation, this 
association has not always implied impairment in liver 
regeneration. Experiments in a telomere restriction 
fragment-deficient mouse model demonstrated that 
liver regeneration after partial hepatectomy was not 
compromised by the loss of telomere integrity[59]. 
Post-hepatectomy regeneration was accomplished, 
increasing cell growth and yielding polyploid cells, 
indicating a switch from a proliferative to a cell growth 
pathway.
Another factor that suggests involvement of the 
decline in liver regeneration with aging is the inhibition 
of regeneration at an epigenetic level. Studies by 
Timchenko’s group[60] indicate that the reduced proli-
ferative response of aged livers is likely to be related 
to alterations in signal-transduction pathways (at the 
translational and/or post-translational levels). The 
decline in the regenerative capacity of old livers seems 
to be related to epigenetic silencing of E2F-regulated 
genes as a result of several age-dependent signal-
transduction pathways. A decline in growth hormone 
with age leads to higher cyclin D3 levels that activate 
cdk4. Activated cdk4 promotes the formation of 
C/EBPα-Brm and CUGBP1-eIF2 complexes in livers of 
old mice. CUGBP1-eIF2 complexes up-regulate HDCA1 
protein levels that, jointly with C/EBPα-Brm complexes, 
bind to E2F-dependent promoters, inhibiting expression 
of E2F-regulated genes and thus liver regeneration. In 
fact, it has been observed that treatment of old mice 
with growth hormone corrects liver proliferation[61].
In addition, hepatocellular response to growth 
factors has been proposed as another mechanism 
implicated in the reduction of liver regeneration 
with aging. The hepatocyte proliferative response to 
epidermal growth factor (EGF) is clearly increased 
in young rats compared to old animals, suggesting 
that aging impairs hepatocyte responsiveness to 
growth factors[53,60]. The problem does not seem to 
be related to the number of EGF receptors or their 
binding capacity but rather to a reduction in receptor 
phosphorylation, a critical step in the EGF-induced 
hepatocyte proliferation pathway[61]. 
Apart from the mechanisms mentioned previously, 
changes in the structure of hepatic sinusoidal endo-
thelium, including a loss of fenestrae and a thickening of 
the endothelial cells (pseudo-capillarization), have also 
been associated with a decrease in liver regeneration 
with aging. Furrer et al[62] demonstrated that pseudo-
capillarization contributes to age-related decline in 
regeneration after hepatectomy in mice. Their data 
demonstrated that treatment with a serotonin receptor 
agonist in old mice restored liver regeneration capacity 
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through a vascular endothelial growth factor (VEGF)-
dependent pathway. In their findings, the serotonin 
receptor agonist resulted in increased systemic VEGF 
availability, up-regulating the number and size of 
endothelial cell fenestrae, improving hepatic blood 
flow, and therefore enhancing the hepatic regenerative 
capacity. In this sense, higher VEGF secretion levels 
have also been detected in cultures of isolated human 
hepatocytes from young donors compared to those 
isolated from older donors[63]. 
Finally, a decline in the hepatic progenitor cell 
population has also been suggested as another 
possible cause of liver regeneration impairment in 
older donors. Ono et al[21] observed that the progenitor 
cell population (Thy-1+) consistently tended to decline 
with age in LDLT. On the other hand, Yousef et al[64] 
recently found that the decline in stem cell function 
with age was largely due to biochemical imbalances 
in the cell niches, demonstrating that aging imposes 
an elevation in transforming growth factor β (TGF-β) 
signaling in the myogenic niche of skeletal muscle and 
in the neurogenic niche of the hippocampus. When 
they interfered with TGF-β levels by systemically 
decreasing TGF-β signaling with a single drug, bringing 
its levels closer to those detected in young mice, these 
authors could simultaneously enhance neurogenesis 
and muscle regeneration in the same old mice, 
findings further corroborated via genetic interference 
with TGF-β. Conboy et al[65] have previously reported 
similar observations in old mice permanently linked 
with their vascular systems (heterochronic parabiosis) 
to young mice. They reported a significant increase 
in proliferation of the aged hepatocyte progenitors in 
the old liver and restored expression of the complex 
c/EBP-alpha to levels seen only in young animals. 
Additionally, Wang et al[66] reported that senescent 
human hepatocytes can restore their proliferative 
capacity after xenotransplantation into mice, a finding 
with a potentially great impact on future studies 
of liver pathology and liver cell therapy. Hence, a 
process that once was thought to be terminal - i.e., 
cell senescence and growth arrest - seems now to be 
tightly associated with the organ microenvironment 
rather than with the actual age of the organism. This 
relationship opens the door to the development of 
novel pharmacological strategies aimed at rejuvenating 
old liver grafts immediately after procurement and 
prior to transplantation. 
Thus, understanding the cellular and molecular 
basis for the reduced proliferative response in old 
livers is important and could indicate how we can 
improve liver regeneration and graft survival in older 
patients. From this perspective, some studies have 
been designed to find specific markers to predict 
function and longevity of transplanted organs. Among 
those senescence markers that have been studied is 
the abovementioned telomere length; others include 
the senescence marker protein-30 (SMP-30), which 
has shown good results in animals that have not 
correlated with results in humans; CDKN2A/p16INK4a, 
which is a good predictor of long-term graft function 
in renal transplantation but has not yet been studied 
in liver models; the cyclooxygenases 1 and 2 (COX-1 
and COX-2); the cell proliferation marker Ki-67; endo-
plasmic reticulum chaperone levels; and cytochrome 
p450 mRNA expression[67].
 In old animals and in elderly humans liver regene-
ration is impaired, and it appears to be the rate of liver 
regeneration, rather than the regenerative capacity, 
that is diminished in the elderly (Table 3). 
These age-related changes could be the factors 
that determine the higher sensitivity of the graft from 
older donor to develop irreversible lesions induced by 
distinct injuries, and results in higher rate of unsuitable 
response in older donor grafts.
CONCLUSION
The age of donors is increasing significantly in recent 
years, and liver grafts previously considered suboptimal 
because they came from elderly donors are nowadays 
used routinely in all centers. Although the various 
existing studies so far have contradictory results, age 
may have a role in the outcome of LT. The use of older 
donors has been linked to a greater number of biliary 
complications in both deceased and LDLT, as well as to 
a poor outcome of HCV recurrence injury. In addition, 
most LT prognostic scores have donor age as a 
fundamental variable. The pathophysiological bases of 
this association are not well established. Liver function 
does not seem to be influenced by aging, but several 
changes at the macroscopic and hepatocellular levels 
have been observed. There are also reported different 
biological changes in aging that lead to a loss of the 
liver’s proliferative response and regeneration. These 
alterations may lead to an impairment of the capacity 
of the liver to manage and overcome liver diseases 
and to face external injuries.
Donor age is not the only relevant factor in the 
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Table 3  Review of cellular and molecular mechanisms 
suggested to be implicated in the loss of aged liver’s 
regenerative capacity
Mechanism Ref.
Telomere shortening Takubo et al[55]
Aikata et al[56]
Aini et al[57]
Transcriptional and post-transcriptonal 
modifications
Timchenko[60]
Wang et al[61]
Hepatocelullar response to growth factors Schmucker[53]
Wang et al[61]
Pseudo-capillarization Furrer et al[62]
Decline of progenitor cell popullations and changes 
in their niches
Ono et al[18]
Yousef et al[64]
Conboy et al[65]
Wang et al[66]
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outcome of LT, however; surgical factors such as 
ischemia time or hemodynamic instability during 
surgery, and recipient factors, such as MELD score, 
are also essential. Therefore, avoiding these factors as 
much as possible in liver transplants performed with 
elderly donors may lead to outcomes similar to those 
with transplants performed with younger donors.
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